Literature DB >> 3572470

Intracarotid VP-16 in malignant brain tumors.

L G Feun, Y Y Lee, W K Yung, N Savaraj, S Wallace.   

Abstract

Twenty-eight patients with malignant brain tumors (16 with primary brain tumors and 12 with brain metastases) progressing after cranial irradiation with or without chemotherapy received varying doses of intracarotid VP-16. Courses of therapy were repeated every 4 weeks along with computerized axial tomography scan and neurologic examination. Of 15 evaluable patients with primary malignant brain tumors, 1 responded to therapy and 5 had no immediate tumor progression for 2-10 months. None of 12 evaluable patients with brain metastases responded to intracarotid VP-16 although 5 had no immediate tumor progression from 1-4 months. Side effects of treatment were uncommon. Using this route of administration, intracarotid VP-16 does not appear to increase response rates in patients with primary malignant brain tumors, compared with results reported for intravenous VP-16.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3572470     DOI： 10.1007/bf00195611

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  10 in total

1.  Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors.

Authors:  H Stähelin
Journal:  Eur J Cancer       Date:  1973-03       Impact factor: 9.162

2.  New implantable continuous administration and bolus dose intracarotid drug delivery system for the treatment of malignant gliomas.

Authors:  T W Phillips; W F Chandler; G W Kindt; W D Ensminger; H S Greenberg; J F Seeger; K M Doan; J W Gyves
Journal:  Neurosurgery       Date:  1982-08       Impact factor: 4.654

3.  VM-26 as a second drug in the treatment of brain gliomas.

Authors:  A Kessinger; H M Lemon; J F Foley
Journal:  Cancer Treat Rep       Date:  1979-03

4.  EPEG, a new antineoplastic epipodophyllotoxin.

Authors:  P J Creaven; L M Allen
Journal:  Clin Pharmacol Ther       Date:  1975-08       Impact factor: 6.875

5.  Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

Authors:  U Tirelli; M D'Incalci; R Canetta; S Tumolo; G Franchin; A Veronesi; E Galligioni; M G Trovò; C Rossi; E Grigoletto
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

6.  Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J M Dennery; R Belanger; J Gerin-Lajoie; V Montpetit; D Nundy; J Prior; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

7.  Etoposide induced blood-brain barrier disruption in rats: duration of opening and histological sequelae.

Authors:  M K Spigelman; R A Zappulla; J A Strauchen; E J Feuer; J Johnson; S J Goldsmith; L I Malis; J F Holland
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

8.  Comparison of CNS penetration, tissue distribution, and pharmacology of VP 16-213 by intracarotid and intravenous administration in dogs.

Authors:  N Savaraj; K Lu; L G Feun; M A Burgess; T L Loo
Journal:  Cancer Invest       Date:  1987       Impact factor: 2.176

9.  Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors.

Authors:  L G Feun; S Wallace; D J Stewart; V P Chuang; W K Yung; M E Leavens; M A Burgess; N Savaraj; R S Benjamin; S E Young
Journal:  Cancer       Date:  1984-09-01       Impact factor: 6.860

10.  Intra-arterial BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system: a preliminary report.

Authors:  H S Greenberg; W D Ensminger; J F Seeger; G W Kindt; F Chandler; K Doan; S R Dakhil
Journal:  Cancer Treat Rep       Date:  1981 Sep-Oct
  10 in total
  9 in total

1.  Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.

Authors:  D Fulton; R Urtasun; P Forsyth
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

Review 2.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

Review 3.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

4.  Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.

Authors:  P Paoletti; G Butti; R Knerich; P Gaetani; R Assietti
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

5.  Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma.

Authors:  T E Elliott; J C Buckner; T L Cascino; R Levitt; J R O'Fallon; B W Scheithauer
Journal:  J Neurooncol       Date:  1991-02       Impact factor: 4.130

6.  Penetration of etoposide into human malignant brain tumors after intravenous and oral administration.

Authors:  K Kiya; T Uozumi; H Ogasawara; K Sugiyama; T Hotta; T Mikami; K Kurisu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 7.  Intra-arterial chemotherapy of primary brain tumors.

Authors:  Herbert B Newton
Journal:  Curr Treat Options Oncol       Date:  2005-11

8.  A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art.

Authors:  Mateusz Pinkiewicz; Milosz Pinkiewicz; Jerzy Walecki; Michał Zawadzki
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

9.  The role of radiotherapy and chemotherapy in the treatment of primary adult high grade gliomas: assessment of patients for these treatment approaches and the common immediate side effects.

Authors:  E E Philip-Ephraim; K I Eyong; U E Williams; R P Ephraim
Journal:  ISRN Oncol       Date:  2012-12-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.